Anti-TAM Drug Development Services

Targeting TAMs: A Breakthrough in Cancer Therapy

Macrophages are an essential component of the innate immune system and are highly specialized in protecting the body against invaders. Macrophage has a significant role in several disorders. Tumor-associated macrophages (TAMs), as a special type of macrophages, play a significant role in several disorders and cancers. They usually facilitate the development and spread of tumors by stimulating angiogenesis, immunosuppression, and cancer cell proliferation. Clinically, several cancers have a worse prognosis when TAMs are present inside the original tumor. Accordingly, targeting TAMs in drug development is expected to lead to substantial breakthroughs in cancer therapy.

Fig.1 TAMs' functions in tumor development. (Kumari & Seung, 2022)Fig.1 Role of TAMs in tumor development.1

Our Anti-TAM Drug Development Services and Current TAM-targeting Therapies

Targeting different pathways of TAM contributes to cancer formulation. Creative Biolabs developed a series of anti-TAM drug development services to aid in anti-cancer drug development, mainly including:

Enhancing the phagocytic activity of TAMs is emerging as a promising approach for cancer treatment. Our approach focuses on targeting the signals that inhibit phagocytosis, to reduce their expression and thereby promote the phagocytosis of TAMs.

The development of malignancy may be successfully inhibited by the selective consumption of M2-like TAMs in pharmacological therapy. To deplete TAMs, we hunt for many signals that are part of pathways that either prevent M2-TAM formation or make M2-TAMs more apoptotic.

Many elements in the tumor microenvironment (TME) affect the recruitment of M2-like TAMs to the tumor site. One strategy for anti-cancer targeting TAMs could be to stop them from recruiting M2-like TAMs. To find novel medications that inhibit TAM recruitment, we focus on the signals that are associated with tumor formation and TAM recruitment.

TME cytokines cause TAMs to transition from M1-like to M2-like, which in turn drives immune suppression and accelerates tumor growth. Therefore, as a novel and effective anti-cancer therapy approach, we attempt to re-educate M2-like TAMs into M1-like TAMs by targeting similar signals.

Disrupting the metabolic shift of TAMs, including changes to their glucose, amino acid, and lipid profiles, may reduce macrophages' capacity to support tumor development, metastasis, and the establishment of an immunosuppressive microenvironment. We aim to disrupt the formation of an immunosuppressive milieu by influencing the metabolic profile.

Fig.2 Methods for cancer therapy that target TAMs. (Li, et al., 2022)Fig.2 Methods for cancer therapy that target TAMs.2

Hot Targets

Services Targets
  • Drug Development Service Targeting Phagocytosis Promotion of TAM
CD47/SIRPα; MHC1/LILRB1; CD24/Siglec10
  • Drug Development Service Targeting TAM Depletion
M2-TAM production inhibition signals; M2-TAM apoptotic promotion signals
  • Drug Development Service Targeting TAM Recruitment Blocking
CSF1-CSF1R signals; CCR2-CCL2 signals; CXCR4-CXCL12 signals; Protein neddylation modification; Others
  • Drug Development Service Targeting TAM Reprogramming
TLRs; miRNA; EGF; PDGF; etc.
  • Drug Development Service Targeting TAM Metabolism
Glucose metabolism; Lipid metabolism; Amino acid metabolism;

Benefits for You

Fig.3 Benefits for you. (Creative Biolabs Original)

To improve cancer therapy and people's quality of life, Creative Biolabs, a frontrunner in tumor research, draws on its employees' vast professional expertise and priceless experience to create powerful tools. If you are interested in our anti-TAM drug development services and want to know more details about it, please don't hesitate to reach out to us.


  1. Kumari, Nisha, and Seung Hong Choi. "Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies." Journal of Experimental & Clinical Cancer Research 41.1 (2022): 68.
Online Inquiry


> Global

Copyright © 2024 Creative Biolabs. All Rights Reserved.